Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX”
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX”
Patented two-fold technology in development to locate, ablate and confirm successful ablation of specific nerves for pain management and other uses.
All safety inputs met with no reported procedure-related side effects.
First-in-human clinical study on track to commence in Q1 2024.
Appointment of Marco Bedoya, a proven leader in medical device mechanical engineering, as Director of Product Development.
Engagements secured with preeminent firms to drive design and development of patented two-fold technology designed to detect problematic neural signals and ablate nerves in one simple procedure for pain management.
Company on track to complete sensing technology and human clinical trial device development in 1H2025.
Live webcast roundtable discussion featuring Autonomix, Knightscope, and Infinity Fuel
Company developing potential breakthrough technology for the nervous system.
Patented two-fold technology that can potentially detect problematic neural signals and ablate nerves in one simple procedure for pain management.
Initially targeting multi-billion-dollar pancreatic cancer market
As part of the event, management will discuss the Company’s innovative technologies in development to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated.
As part of the event, Lori Bisson, Chief Executive Officer of Autonomix will discuss its innovative technologies in development to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated.
“We are pleased to welcome Dr. Capelli to our board of directors. He brings with him a wealth of knowledge and expertise, amassed over a noteworthy career. We believe Dr. Capelli will undoubtably be a valuable part of the team as we continue to advance the Company and our novel approach to how diseases involving the peripheral nervous system are diagnosed and treated,” commented Lori Bisson, Chief Executive Officer of Autonomix.
Company developing innovative two-fold technology designed to both detect the neural signals relating to pain or disease and ablate them in one simple procedure. Ongoing progress toward launch of first-in-human clinical trial for the treatment of pancreatic cancer pain and pancreatitis pain in 2024.
Autonomix Medical, Inc.
21 Waterway Ave, Suite 300
The Woodlands, TX 77380
LEGAL DISCLAIMER
This presentation (the “presentation”) has been prepared for use by Autonomix Medical, Inc. (“Autonomix”) in connection with their proposed offering. This presentation is for information purposes only and is being provided to assist interested parties in making their own evaluation with respect to a potential investment, and for no other purpose. This presentation may not be reproduced or redistributed, in whole or in part, without the prior written consent of Autonomix. Autonomix does not make any representation or warranty as to the accuracy or completeness of the information contained in this presentation. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in connection with the proposed offering and is not intended to form the basis of any investment decision. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in the transactions contemplated in this presentation.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) NOR ANY STATE OR TERRITORIAL SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.
FORWARD-LOOKING STATEMENTS
This presentation may include ‘’forward-looking statements.‘’ To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Autonomix Medicial, Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
USE OF DATA
The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. Autonomix assumes no obligation to update the information in this presentation.
Autonomix is committed to protecting your privacy. This Privacy Policy outlines our practices concerning the collection, use, and protection of your personal information when you visit our website or use our services.
1. Information We Collect
We may collect personal information that you voluntarily provide to us, including but not limited to:
We may also collect non-personal information, such as:
2. How We Use Your Information
We may use your personal information for various purposes, including but not limited to:
3. Cookies and Tracking Technologies
We use cookies and similar tracking technologies to collect information about your browsing behavior on our website. You can manage your cookie preferences through your browser settings.
4. Disclosure of Your Information
We may share your personal information with third parties under the following circumstances:
5. Your Rights
You have the right to:
6. Data Security
We take reasonable measures to protect your personal information from unauthorized access, disclosure, alteration, or destruction. However, no method of data transmission over the internet or electronic storage is entirely secure. Therefore, we cannot guarantee its absolute security.
7. Children’s Privacy
Our website and services are not intended for children under the age of 13. We do not knowingly collect personal information from children. If you believe that a child has provided us with their personal information, please contact us, and we will take appropriate steps to delete the information.
8. Changes to this Privacy Policy
We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. We encourage you to review this Privacy Policy periodically for any updates.
9. Contact Us
If you have any questions or concerns about this Privacy Policy or our data practices, please contact us at autonomix@jtcir.com.
1. Acceptance of Terms
By accessing and using this website, you agree to abide by these Terms and Conditions, as well as any applicable laws and regulations. If you do not agree with these terms, please refrain from using this website.
2. Use of Content
All content on this website, including but not limited to text, images, graphics, videos, and logos, is the property of Autonomix or its affiliates and is protected by intellectual property laws. You may not reproduce, distribute, or display any content without prior written permission.
3. User Conduct
You agree not to engage in any of the following activities while using this website:
4. Privacy Policy
Your use of this website is also governed by our Privacy Policy, which outlines how we collect, use, and protect your personal information. By using this website, you consent to the practices described in our Privacy Policy.
5. Links to Third-Party Websites
This website may contain links to third-party websites. These links are provided for convenience only, and Autonomix does not endorse or assume responsibility for the content or practices of these websites. Accessing third-party websites is at your own risk.
6. Disclaimer of Warranties
This website is provided “as is,” without any warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, or non-infringement. Autonomix does not warrant that the website will be error-free or uninterrupted.
7. Limitation of Liability
To the fullest extent permitted by law, Autonomix shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of or related to your use of this website. This includes but is not limited to any loss of data or profits.
8. Governing Law
These Terms and Conditions shall be governed by and construed in accordance with the laws of the United States. Any disputes arising under these terms shall be subject to the exclusive jurisdiction of the courts in the United States.
9. Changes to Terms and Conditions
Autonomix reserves the right to modify or revise these Terms and Conditions at any time. It is your responsibility to review this page periodically for updates. Your continued use of the website after any changes signifies your acceptance of the revised terms.
10. Contact Information
If you have any questions or concerns about these Terms and Conditions, please contact us at autonomix@jtcir.com.